Sugammadex and Neostigmine, two agents for the reversal of neuromuscular blockade following surgery, have been subject to several studies comparing their clinical and cost effectiveness. In settings where patients have full neuromuscular recovery (Train-of-four ratio ≥ 0.9) prior to extubation, the economic impact of Sugammadex is related to a reduction in recovery and operating room (OR) staff times. In settings where full neuromuscular recovery is not verified, economic impact primarily derives from avoided complications of residual neuromuscular blockade. This study aimed to determine the potential cost impact of use of Sugammadex in Turkish hospitals. The timeline of the model was one year.
OBJECTIVES
The timeline of the model was one year.
Although cost of acquiring Sugammadex is considerably higher than Neostigmine, the cost offsets for hospitals might be substantial. Real world data are needed to understand economic outcomes in clinical practice as the magnitude of offsets depends on assumptions concerning the frequency and intensity with which events are clinically managed. 
Institution in Primary Analyses
Number of operating rooms (ORs) at institution
